Figure 1.
Figure 1. Genetically imposed uPA deficiency is protective against the development of CIA in DBA/1 mice. (A) Kaplan-Meier log-rank analysis indicating the percentage of WT and Plau−/− mice with macroscopic arthritis in the paws is shown for the 3-week evaluation period after the second CII immunization. Note that ∼75% of DBA/1 Plau−/− mice remained arthritis-free based on visible inspection through the CIA study period. (B-C) The median arthritis index revealed a significant diminution in number of arthritic joints per mouse in the absence of uPA (B), with individual scores indicated for day 42 (C). (D-E) The median arthritis severity for the same cohort of mice revealed a significant reduction in paw swelling for CIA-challenged Plau−/− mice (n = 16 in the WT group and n = 11 in the Plau−/− group) (D), with individual scores indicated for day 42 (E). (F) Kaplan-Meier log-rank analysis indicating the percentage of WT and Plaur−/− mice with macroscopic arthritis in the paws is shown for the 3-week evaluation period after the second CII immunization. Note that ∼60% of DBA/1 Plaur−/− mice remained arthritis-free based on visible inspection through the CIA study period. (G and H) The median arthritis index revealed a significant diminution in number of arthritic joints per mouse in the absence of uPAR (G), with individual scores indicated for day 42 (H). (I-J) The median arthritis severity for the same cohort of mice revealed a significant reduction in paw swelling for CIA-challenged Plaur−/− mice (n = 13 in the WT group and n = 14 in the Plaur−/− group) (I), with individual scores indicated for day 42 (J). P values were determined by Mann-Whitney U test. *P < .05.

Genetically imposed uPA deficiency is protective against the development of CIA in DBA/1 mice. (A) Kaplan-Meier log-rank analysis indicating the percentage of WT and Plau−/− mice with macroscopic arthritis in the paws is shown for the 3-week evaluation period after the second CII immunization. Note that ∼75% of DBA/1 Plau−/− mice remained arthritis-free based on visible inspection through the CIA study period. (B-C) The median arthritis index revealed a significant diminution in number of arthritic joints per mouse in the absence of uPA (B), with individual scores indicated for day 42 (C). (D-E) The median arthritis severity for the same cohort of mice revealed a significant reduction in paw swelling for CIA-challenged Plau−/− mice (n = 16 in the WT group and n = 11 in the Plau−/− group) (D), with individual scores indicated for day 42 (E). (F) Kaplan-Meier log-rank analysis indicating the percentage of WT and Plaur−/− mice with macroscopic arthritis in the paws is shown for the 3-week evaluation period after the second CII immunization. Note that ∼60% of DBA/1 Plaur−/− mice remained arthritis-free based on visible inspection through the CIA study period. (G and H) The median arthritis index revealed a significant diminution in number of arthritic joints per mouse in the absence of uPAR (G), with individual scores indicated for day 42 (H). (I-J) The median arthritis severity for the same cohort of mice revealed a significant reduction in paw swelling for CIA-challenged Plaur−/− mice (n = 13 in the WT group and n = 14 in the Plaur−/− group) (I), with individual scores indicated for day 42 (J). P values were determined by Mann-Whitney U test. *P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal